Cambrian Biopharma

A portfolio approach to drug aging itself

Cambrian Biopharma is a longevity-focused clinical holding company with 14 drug candidates targeting the biological drivers of aging. Rather than betting on a single mechanism, Cambrian takes a portfolio approach — advancing multiple programs across senolytics, epigenetic modulation, proteostasis, and metabolic optimization simultaneously. Valued at $1.8 billion, Cambrian is one of the most well-funded longevity companies in the world, aiming to develop therapies that extend healthy lifespan by targeting the root causes of age-related decline rather than individual diseases.